Confirm the reasons why NASH is a serious condition as defined in 21 CFR regulation. Understand the importance of early clinical development and proof-of-concept trials. Describe …

2020年11月13日 · We conducted a 72-week, double-blind phase 2 trial involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3. Patients were randomly …

2021年5月8日 · We identified 3 groups known to be at greatest risk of NAFLD/NASH-related fibrosis. Effective screening and timely diagnosis of fibrosis can prevent progression to …

2021年10月20日 · Nonalcoholic fatty liver disease (NAFLD) affects more than one quarter of the adult population globally and is closely linked to underlying obesity, type 2 diabetes, and...

We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across …

NAFLD is the most common cause of liver disease worldwide, and its prevalence is significantly increasing. Studies have shown that it is associated with comorbidities such as diabetes, …

NASH Trial Design and Considerations Enrollment Criteria •Need adequate rationale and justification •Use of noninvasive, disease-specific biomarkers (e.g., an aminotransferase), total …

Drug development targeting pathological pathways in NASH have exploded in the past decade, with numerous new drugs under investigation. This review summarizes the results of pivotal …

摘要: 非酒精性脂肪性肝炎 (NASH)日益成为肝硬化、肝细胞癌和肝脏相关死亡的常见原因，目前尚无已批准上市的NASH有效治疗药物。 因此，迫切需要NASH新药以改善临床相关终点，减轻 …

2020年12月1日 · Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management …